Single Administration Study of Sotatercept (MK-7962) in Healthy Japanese Participants

A Single-Administration Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Sotatercept (MK-7962) in Healthy Japanese Participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051220078

Enrollment

Registered

2022-08-20

Start date

2022-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension

Interventions

Panel A: MK-7962 0.3mg/kg or placebo, Panel B: MK-7962 0.7mg/kg or placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Be in good health based on medical history, physical examination, vital signs measurements, and 12-Lead ECGs performed before randomization. 2) Be in good health based on laboratory safety tests obtained at the screening visit and before administration of the initial dose of study intervention. 3) Must have a body weight of at least 40 kg, BMI >=18.5 and <=30 kg/m2, inclusive.

Exclusion criteria

Exclusion criteria: 1) Have prior exposure to sotatercept or luspatercept. 2) History of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. 3) History of cancer (malignancy).

Design outcomes

Primary

Measure	Time frame
Adverse event, MK-7962 PK	—

Secondary

Measure	Time frame
Anti-drug antibody	—

Contacts

Public ContactMSDJRCT inquiry mailbox

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026